HCPCS Level II code C9257 denotes the injection of bevacizumab in a 0.25 mg unit. Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody used across oncology and certain ophthalmologic applications; a code for a small drug quantity like C9257 enables itemized billing for incremental dosing and supports facility and professional payment workflows. Nationally, accurate coding for biologic injections affects drug cost reporting, prior authorization processes, and patient cost-sharing calculations.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on clinical use and administration setting, typical billing considerations tied to a unit-based HCPCS drug code, and what to expect in payer coverage patterns. The publication outlines benchmark elements such as common payer approaches to unit pricing, coding validation checkpoints, and links between dose-based codes and prior authorization requirements. It also summarizes relevant policy drivers that influence nationwide utilization and reimbursement of injectable biologics.

This summary serves clinicians, billing managers, and policy analysts seeking a concise reference to the code's clinical meaning, typical site of service, and the payer landscape nationally. Data not available in the input is noted where applicable.